TP53 mutations in the DNA binding domain occur in approximately 50–70% of PDA cases and with variable frequency in PanIN-3 lesions, supporting the idea that PanIN-3 can show different levels of malignancy and PDA subtypes [16,26,27]. Here, TP53 is linked to Patent ductus arteriosus.